

Acute respiratory infection: first clinical manifestation of active infection with cytomegalovirus in HIV patients presenting to the emergency department

PERELLÓ R¹, VERGARA A², CAMÓN S¹, SAUBI N³, ETO Y³, QUIRÓS C, PRIU I¹, MORENO A³, MARTÍNEZ E³, MARCOS MA²

¹ Emergency Department, Hospital Clínic, Barcelona, Spain

² Microbiology Department, Hospital Clínic, Centro de investigación internacional (CRESIB) Hospital Clínic, Universidad de Barcelona, Barcelona, Spain

³ Infectious diseases, Hospital Clínic, IDIBAPS, Universidad de Barcelona, Barcelona, Spain

Corresponding author:

Perelló R

Emergency Department

Hospital Clínic

C/Villarroel 170, Barcelona, Spain

Phone: +34932275400 (ext 4031)

E-mail: rperello@clinic.cat

ABSTRACT

Introduction. Traditionally, digestive and ophthalmic symptoms have been described as predominant in the clinical presentation of active infection with cytomegalovirus (AICMV). Nevertheless, it seems that this has changed following the introduction of antiretroviral therapy (ART). Nowadays, respiratory infection (RI) in HIV-infected patients is the first reason for consulting an Emergency Department (ED). Among these patients, the mortality is important.

Aim. To determine if RI in HIV-infected patients is a common manifestation of AICMV and to describe the changes in clinical presentation of AICMV in relation to what was previously described.

Methods. A single-center, retrospective study was conducted over the duration of nine years (2005-2015). All HIV patients who consulted our emergency department with respiratory symptoms and were diagnosed with AICMV were included. Isolation of other co-infecting microorganisms and mortality in the series are also described.

Results. 56 HIV-infected patients with AICMV were identified. RI was diagnosed in 34 (61%), 31(91%) patients had pneumonia and 3(9%) pulmonary tuberculosis. The most frequently isolated microorganism was *P. jirovecii*, in 21 (68%) patients.

Bacteria were isolated in five patients (15%). Five patients died from RI (9%). No patient had acute retinitis or any other ophthalmic involvement.

Conclusion. Clinical manifestation of AICMV in HIV patients has changed, and RI is the most common manifestation, caused by opportunistic microorganisms with 9% mortality.

Key words: HIV, infection respiratory, pneumonia, CMV

INTRODUCTION

Human cytomegalovirus (CMV) infection is highly prevalent in the world, especially in developing countries where 90% of the population is infected with this virus, while infection is estimated at 60% in developed countries. (1) In immunocompetent individuals, the infection is usually asymptomatic, mild or causes a mononucleosis syndrome but in immunosuppressed patients it behaves as an opportunistic pathogen, causing severe damage. (2)

Specifically in HIV-infected patients with severe immune suppression, it manifests in up to 40% of them throughout their life, usually as ophthalmic manifestations or digestive. (3) However, following the introduction of combination antiretroviral therapy (cART), prognosis has improved,

and consequently active infection with cytomegalovirus (AICMV) has decreased. (4)

Respiratory infection (RI) is one of several indicators of AICMV, and the main cause for attending an Emergency Department (ED) in HIV-infected patients. Community-acquired pneumonia is the leading cause of death in these patients. (5) Although the incidence of RI has decreased, and its etiology has changed due to the introduction of cART, it has a non-negligible mortality and often requires admission to an intensive care unit (ICU). (6)

The study objectives were to clarify, in a cohort of HIV-infected patients, if the usual clinical manifestations of AICMV have changed, and if RI has an important role in the presentation of AICMA. Furthermore, we wanted to find out which microorganisms cause it, and what the 30-day mortality is.

METHODS

Design, setting, and population

This is a single-center retrospective study taking place during the course of nine years (2006-2015) and performed at our hospital which conducts annual monitoring of 5000 HIV-infected patients. All patients with HIV infection who attended our ED with respiratory symptoms and were diagnosed with AICMV were included.

Study protocol

AICMV was defined as the isolation of the virus or evidence of CMV replication, regardless of symptoms, by polymerase chain reaction (PCR); culture in any fluid or body tissue; and CMV disease, where the infected patient, besides virus replication, shows symptoms or signs of disease (viral syndrome or visceral involvement). (7,8) For the diagnosis of pneumonia, regardless of etiology, the criteria of the Infectious Diseases Society of America were applied. (9) Severe immunosuppression was defined as the presence of a CD4 count of less than 200 cells/ μ l in blood.

Measurements

The following epidemiological, clinical and laboratory variables were collected from patients: sex, age, previous opportunistic infections, associated comorbidities, route of HIV transmission, toxic habits, cART, number of CD4, CD8 lymphocytes and HIV viral load (VL) (prior to admission), coinfection with hepatitis C virus (HCV), target organ of CMV infection, presence of fever, need for mechanical ventilation (MV), number of total leukocytes, platelets, hemoglobin, liver profile, ICU admission, and 30-day mortality.

To determine the presence of pathogens, the results of blood cultures (Bactec 9240; Becton Dickinson), Gram stain and culture of respiratory samples, Ziehl-Neelsen stain and culture of mycobacteria, silver stain to detect *P. jirovecii*, and PCR to identify the presence of other respiratory viruses, were collected. For the diagnosis of CMV, viral culture of bronchoalveolar lavage (BAL) and CMV detection by real-time quantitative PCR (Q-CMV Real Time, Nanogen) in plasma, BAL and / or biopsy of the affected organ, were performed.

Statistical analysis

Categorical variables were expressed as frequencies and percentages, and continuous variables were expressed as mean and standard deviation. Results were considered statistically significant if the p-value was less than 0.05. To evaluate the relationship between quantitative variables, T-test for independent samples was used in normally distributed variables and U-Mann Whitney in those not normally distributed. The chi-squared was used to evaluate the relationship between qualitative variables. All statistical analyses were calculated using SPSS version 20.0 (Chicago, IL, USA).

RESULTS

56 HIV-infected patients were identified with AICMV. The mean age was 43 years, 44 (79%) were male, and 6 (11%) had HCV coinfection. HIV transmission was through sexual contact for 48 (88%) patients and IDUs (drug abuse) for 8 (22%). Only 15 (27%) were receiving cART. The median CD4 count was 31 cells/ μ l (IRQ = 61), HIV VL 284050 copies / ml (IRQ = 631,625), the average blood CMV VL was 68569.94 \pm 26718,5 copies / ml, and in BAL, 3359.0 \pm 47985,93 copies / ml. Nineteen (34%) patients were admitted to ICU. The most common clinical sign was fever (59%). The other variables are shown in table 1.

Out of the 56 patients who had AICMV, 34 (61%) of them presented with RI, as a clinical manifestation, to the ED. The lower airways were always affected of which 31 (92%) patients had pneumonia and 3 (8%) had pulmonary tuberculosis (TB). In 29 (85%) patients, CMV coinfection was detected with other microorganisms: Mycobacterium tuberculosis in 3 (8%), *P.*

jirovecii in 21 (68%), *Haemophilus influenzae* in 2 (6%), *Klebsiella pneumoniae* in 1 (3%), *Pseudomonas aeruginosa* in 1 (3%), *Streptococcus pneumoniae* in 1 (3%). In five (16%) patients, CMV was the only pathogen isolated.(table 1). All patients diagnosed with pneumonia caused by *P. jirovecii* or TBC showed a degree of severe immunosuppression. In our series, no patient had acute retinitis or any other ophthalmic involvement and only 8 patients (14%) presented with digestive symptoms. Others clinical manifestations are shown in table 2.

The overall 30-day mortality was 18% (10 patients) and 5 (50%) of them had a respiratory infection, 2 (12%) had an infection of the central nervous system (cerebral toxoplasmosis), 1 (6%) died from liver failure (HCV coinfecting patient), 1 (6%) from hematologic disease (lymphoma) and 1 (6%) from intestinal infection (*lamblia giardiasis*). Death from respiratory infection, compared to the total sample, occurred in five patients (9%): in 3 (60%) cases due to pneumonia by *P. jirovecii*, in 1 (20%) by *H. influenzae* and in 1 (20%) by *S. pneumoniae*. The only variables associated with mortality were: the need for ICU admission (X² = 17.7; p <0.001) and the need for MV (X² = 28.3; p <0.001) (table 3). The mortality rate for patients admitted to the ICU was 47%.

The CMV viral load in the blood showed no discriminative power for mortality (30846.7 \pm 69235.8 vs. 2100034.8 \pm 573143.6; U=84; p=0.197), while the viral load in BAL was significantly higher in patients who died (103648.0 \pm 40658.7 vs 9929.3 \pm 16066.3; U=12; p=0.208).

Table 1. Descriptive analysis of the HIV and active infection by cytomegalovirus (AICMV) population.

Age (mean)	43
Male (%)	44 (79%)
ART (%)	15 (27%)
HCV Co-infection (%)	6 (11%)
Drugs (%)	9 (16%)
CD4 (median) cel/ μ l	31 cel/ μ l (IRQ=61)
HIV Viral load (mean) copies/ml	284050 copies/ml (IRQ=631625)
Previous opportunistic infection (%)	15 (27%)
ICU admission (%)	19 (34%)

Mechanical ventilation (%)	12 (21%)
Overall mortality (%)	10 (18%)
Fever (%)	33 (59%)
Associated comorbidities (%)	20 (36%)
Mortality from respiratory infection (%)	5 (9%)
CMV viral load in blood	11,15 copies/ml (IRQ=85.24)
CMV viral load in BLA	66 copies/ml (IRQ=1466.9)
Sexual transmission (%)	48 (88%)
Respiratory isolations (%)	34 (61%)
Pneumocystis jirovecii	21 (68%)
Haemophilus influenzae influenzae	2 (6%)
Klebsiella pneumoniae	1 (3%)
Pseudomona aeruginosa	1 (3%)
Streptococcus pneumoniae	1 (3%)
CMV	5 (16%)
Mycobacterium tuberculosis	3 (9%)

ART, Antiretroviral therapy; BAL, bronchoalveolar lavage; ICU, Intensive care unit; HCV, Hepatitis C virus.

Table 2. Active infection by cytomegalovirus (AICMV) clinical manifestations.

Respiratory (n)	34 (61%)
Digestive (n)	8 (14%)
Neurological (n)	8 (14%)
Dermatological (n)	2 (3%)
Hematological (n)	3 (5%)
Ophthalmic (n)	0 (0%)
Cardiological (n)	1 (2%)

Table 3. Predictors of mortality.

Qualitative Variables and Mortality					
VARIABLE		Association	CHI ²		P
Gender		No	0.902		0.761
ART		No	2.597		0.107
HIV transmission		No	1.141		0.285
HCV coinfection		No	0		1
Comorbidities		No	0		1
Smoker		No	0		1
Drugs		No	0.221		0.638
Opportunistic infections		No	1.936		0.164
ICU admission		YES	17.7		<0.001
Mechanical ventilation		YES	28.3		<0.001
Fever		NO	0.071		0.965
Clinical manifestations		NO	0.078		0.781
Quantitative Variables and Mortality					
	MORTALITY	N	Median	IQR	p
CD4 lymphocytes	YES	10	82.2	54	0.672
	No	46	114.6	60	

CD8 lymphocytes	YES	10	540.4	633	0.482
No	46	710.7	534		
Viral load VIH	YES	10	1889327.1	894828.0	0.549
No	46	850621.2	610775		
%CD4	YES	10	11.3	9.0	0.278
No	46	8.1	6.2		
%CD8	YES	10	64.5	15.3	0.702
No	46	62.4	24.3		
Leukocytes	YES	10	6890.0	2950	0.854
No	46	7236.5	490		
Hemoglobin	YES	10	11.4	3.15	0.753
No	46	11.6	2.6		
Platelets	YES	10	225800.0	162500	0.536
No	46	330413.0	196750		
GOT	YES	10	44.0	60	0.738
No	45	49.0	36		
Direct bilirubin	YES	9	0.5	0.6	0.080
No	45	0.2	0.1		
GPT	YES	10	26.0	15	0.269
No	46	46.5	29		
GGT	YES	10	114.5	110	0.995
No	39	114.0	42		
LDH	YES	10	856.5	546	0.622
No	42	778.8	643		

ART, Antiretroviral therapy; GGT, gamma glutamyl transpeptidase; GPT, glutamic-pyruvic transaminase; IQR, interquartile range; LDH, lactate dehydrogenase; OT, Glutamic oxaloacetic transaminase; ICU I, Intensive care unit; HCV, hepatitis C virus.

DISCUSSION

Lower respiratory tract infection is the most common infection in HIV-infected patients, and sometimes it is the first clinical manifestation of infection. (10) Our study confirms this and adds that this is also the case in AICMV. Pneumonia was the most common presentation of respiratory infection (31 cases) and the most common cause was *P. jirovecii*, unlike what was described in the literature previously, where the main bacterial etiology remains mainly at the expense of *S. pneumoniae*. (11) In our series, there were only four bacterial isolates and among them *S. pneumoniae* was the only one. This is due to the degree of severe immunosuppression in our patients who had not started ART (because being infected with HIV was unknown before admission to ED), or because they were in the first 6 months of treatment, where ART had not yet reached

its maximum effectiveness. Pulmonary involvement with CMV infection in the form of pneumonitis has a similar presentation to the one with *P. jirovecii* infection, which can lead to confusion and errors in treatment. (12) The patients with TB did not show any mortality in our series. However, this information should be taken with caution because our sample size is very small. Recent World Health Organization (WHO) studies also show that TB is responsible for up to one quarter of deaths of HIV-infected patients, especially when the infection is advanced. (13,14)

The highest percentage of respiratory manifestations in HIV-infected patients with AICMV shows a change in clinical presentation. Until now, according to the data reported in the scientific literature, ocular and gastrointestinal manifestations are the ones seen most frequently. (15) In our series, despite the high number of

patients with immunosuppression, it was surprising that no patient had retinitis, but this is consistent with previous studies that have shown a decrease in retinitis, caused by CMV, in the cART era. (16)

The overall mortality in this study was 18%, and the leading cause of death was respiratory infection (9%). Mortality was higher in patients admitted to the ICU, as in previous studies. (17) Our work contrasts with the findings of Lichtner et al. (18) where cardiovascular and neurological events, attributed to immune dysfunction due to HIV / CMV coinfection, were the leading causes of death. CMV is an immunomodulatory virus which favors the appearance of opportunistic diseases, and the vast majority of HIV patients have a coinfection at some point in their life, leading to increased activation of the immune system, even if they are on cART, (19) with a consequent increase in mor-

idity and mortality. Early identification of CMV infection can prevent the onset of opportunistic infections. Based on the above, we believe that detection should be early, requesting, if there is any suspicion, diagnostic tests in the same HED and BAL since, as we have seen, higher viral load of CMV in BAL leads to increased mortality.

LIMITATIONS

Among the limitations of our study we emphasize that this is a single-center, retrospective study based on laboratory confirmation of CMV infection with a small number of cases.

CONCLUSION

In HIV patients, respiratory infection is the most common manifestation of AI-CMV, and is caused by opportunistic microorganisms, resulting in a 9% mortality.

REFERENCES

1. Sanbonmatsu Gámez S, Ruiz MP, Navarro Marí JM. Infection by human cytomegalovirus. *Enferm Infecc Microbiol Clin* 2014;32:15-22.
2. Komdevall MJ, Mollema L, Tchernieva I, Van der Klis F, Kroes AC, Qudesluys-Murphy AM, et al. Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications. *J Clin Virol* 2015;63:53-8.
3. Bowen EF, Griffiths PD, Davey CC, Emery VC, Johnson MA. Lessons from the natural history of cytomegalovirus. *AIDS* 1996;10:S37-41.
4. Crum NF, Riffenburg RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART eras. *J Acquir Defic Syndrom* 2006;11:194-200.
5. Camón S, Perelló R, Escoda O, Escoda R, Aguilar N, Saubi N, et al. (2014) Reason for HIV Patients Consultation to the Emergency Department in the HAART Era: Incidence and Mortality. *J AIDS Clin Res* 5:340.
6. Perelló R, Escoda O, Camón S, Miró Ò, Castañeda M, Moreno A, et al. Changes in the etiology, incidence and prognosis of acute respiratory track infections, in human immunodeficiency virus patients. *Enferm Infecc Microbiol Clin* 2015;33:243-7.
7. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Transplantation Society International CMV Consensus Group. Update international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. *Transplantation* 2013;96:333-60.
8. Torre-Cisneros J, Fariñas MC, Castón J.J, Aguado J.M, Cantisán S, Carratalá J, et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. *Enferm Infecc Microbiol Clin* 2011;29:735-58.
9. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community acquired pneumonia in adults: guidelines for management. *Clin Infect Dis* 1998;26:811-38.
10. Ojha CR, Rijal N, Khagendra KC, Palpasa K, Kansakar P, Gupta BP, et al. Lower respiratory tract infections among HIV positive and control group in Nepal. *Virus disease* 2015;26:77-81.
11. Cilloniz C, Torres A, Polverino E, Gabarrus A, Amaro R, Moreno E, et al. Community-acquired respiratory infections in HIV-infected patients: microbial aetiology and outcome. *Eur Respir J* 2014;43:1698-708.
12. Katsidzira L, Fana GT, Makunike-Mutasa R, Ferrand RA. Pneumomediastinum in an HIV-infected patient with cytomegalovirus pneumonitis. *Int J STD AIDS* 2011;3:179-80.
13. WHO fact sheet on tuberculosis (TB) [Online]. October 2015. Reviewed March 2016; Available from: URL:<http://www.who.int/mediacentre/factsheets/fs104/en/> Fact sheet N8104.
14. Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. *Lancet* 2016;387:1198-209.
15. Podlasin RB. CMV infection in HIV-patients. *Przegl Epidemiol* 2007;61:629-37.
16. Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. *JAMA* 2000;283:653-7.
17. Papazian L, Hraiech S, Lehingue S, Roch A, Chiche L, Wiramus S. Cytomegalovirus reactivation in ICU patients. *Intensive Care Med* 2016;42:28-37.
18. Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. *J Infect Dis* 2015;211:178-86.
19. Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. *Curr Opin HIV AIDS* 2016;11:191-200.